XVIVO — Xvivo Perfusion AB Income Statement
0.000.00%
Last trade - 00:00
- SEK10.19bn
- SEK9.68bn
- SEK597.54m
2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 221 | 180 | 258 | 415 | 598 |
Cost of Revenue | |||||
Gross Profit | 163 | 130 | 188 | 297 | 445 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 217 | 226 | 277 | 409 | 524 |
Operating Profit | 3.94 | -45.7 | -18.5 | 6.41 | 73.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 5.29 | -57.3 | 6.67 | 22.3 | 94.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4.94 | -43.7 | 8.15 | 18.4 | 91.8 |
Net Income Before Extraordinary Items | |||||
Net Income | 4.94 | -43.7 | 8.15 | 18.4 | 91.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 4.94 | -43.7 | 8.15 | 18.4 | 91.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.186 | -1.61 | 0.283 | 0.852 | 2.11 |
Dividends per Share |